Jon started his career in academia as a member of scientific staff in the Biochemistry Department, Imperial College and then as a Senior Scientific Officer with the Medical Research Council Toxicology Unit. Jon joined Cambridge Antibody Technology (CaT), in 1992 as a Senior Scientist, initially working on several drug discovery projects. Jon then helped establish the CaT process development group before moving across to operational management. Jon held the post of VP Site General Manager, at what was MedImmune, a wholly-owned subsidiary of AstraZeneca, formed through the merger of CaT and MedImmune where Jon was responsible for leading the site operations of the Cambridge R&D facilities. Currently Jon is Chief Operating Officer of Iontas, a well-known antibody engineering CRO.
Jon is the current Chair of the Board of One Nucleus and holds several other directorships and NED appointments.
Jon has a MPhil in molecular biology/cellular pathology, is a Chartered Biologist, a Fellow of the Royal Society of Biology, the Royal Society of Arts and Manufacturing and Fellow of the Institute of Directors.